Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Share News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.50
Bid: 9.30
Ask: 9.50
Change: -0.35 (-3.59%)
Spread: 0.20 (2.151%)
Open: 9.55
High: 10.00
Low: 9.50
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: F&C Investment Trust hires CBI chief economist

Mon, 29th Mar 2021 15:13

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Monday and not separately reported by Alliance News:

----------

F&C Investment Trust PLC - aims for long-term growth and income by investing in listed equities globally - Appoints Rain Newton-Smith as independent non-executive director, starting May 11. Newton-Smith will replace Roger Bone, who is retiring. She is chief economist at the Confederation of British Industry. Previous to the CBI, she was head of Emerging Markets at Oxford Economics. FTSE 250-listed F&C Investment Trust bills itself as the world's oldest collective investment scheme, having launched in 1868.

----------

Spirent Communications PLC - Crawley, England-based provider of testing, analytics and security for telecommunications networks - Appoints Maggie Buggie as non-executive director with effect on April 29. Buggie is currently chief business offer at SAP Services, which is part of Walldorf, Germany-based enterprise software developer SAP SE.

----------

Vesuvius PLC - London-based molten metal flow engineering - Hires Dinggui Gao as non-executive director, starting on Thursday. He currently is managing director of China for Formel D Group, a German service provider to the automotive and components supply industry.

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery - Hires Karl Keegan as chief financial officer, effective immediately. Keegan was most recently chief executive officer of privately held Hox Therapeutics Ltd.

----------

Okyo Pharma Ltd - London-based biotechnology company focused on treatments of inflammatory dry eye diseases and ocular pain - Hires Rajkumar Patil as chief scientific officer. Says Patil has 30 years of ophthalmic and pharmaceutical research and development experience, including with Ora Inc and iVeena Delivery Systems. He also worked at the Alcon/Novartis Institute of Biomedical Research.

----------

Serinus Energy PLC - oil and gas exploration and production in Tunisia and Romania - Dawid Jakubowicz resigns immediately from board, while Eleanor Barke won't stand for re-election to the board at the May 13 annual general meeting. In their place, Serinus hires Natalie Fortescue and Jon Kempster. Fortescue was an investment banker at Investec and Oriel Securities. She joined Genel Energy PLC to establish the investor relations department and also worked with Premier Oil PLC on its reverse takeover by Chrysaor Energy Ltd. Kempster has held CFO positions at companies including London listings Frasers Group PLC and Wincanton PLC, and he currently is interim CFO of FireAngel Safety Technology Group PLC. Kempster also currently is a non-executive director of Bonhill Group PLC, Redcentric PLC and Ted Baker PLC.

----------

Fragrant Prosperity Holdings Ltd - seeking acquisition in cannabis therapeutics - Hires Daniel Reshef as non-executive director starting on Wednesday. Reshef has had a 25-year career in drug development, including with Hoffman La Roche, Genentech and Bristol Myers Squibb Co.

----------

French Connection Group PLC - London-based fashion retailer - Hires Neil Page as independent non-executive director. Page was CFO of retailer Carpetright PLC. French Connection entered a formal sales process at the beginning of month after receiving two separate takeover approaches.

----------

Braveheart Investment Group PLC - makes strategic investments in companies it thinks will outperform - Jonathan Freeman steps down as non-executive director "to devote more time to his other business interests". Starts process for finding a new non-executive director.

----------

Arix Bioscience PLC - venture capital investor in biotech companies - Pauses hire of James Noble and Axel Wieandt as non-executive directors, citing recently announced strategic review, which encompasses board composition.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

Read more
16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

Read more
30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

Read more
24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

Read more
14 May 2013 09:46

e-Therapeutics pleases with pipeline progress

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo

Read more
14 May 2013 08:04

Tuesday broker round-up UPDATE

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral

Read more
10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

Read more
19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

Read more
11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

Read more
23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

Read more
22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

Read more
22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

Read more
15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

Read more
14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

Read more
4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.